Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampreloxetine DDI Study with Fluvoxamine, Itraconazole, and Smoking
NCT03432793Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Feb 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ampreloxetine in Neurogenic Orthostatic Hypotension (nOH) (2 arms), sponsored by Theravance Biopharma, Inc. Primary endpoint: Change in TD-9855 plasma exposure when administered with itraconazole or fluvoxamine at Day 24. Started Feb 2018; status: completed.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on NCT03432793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432793.